Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | CCR3 | P51677 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4577321 | 0.89 | MEN1 (0.58) | MEN1KMT2ASMN1; SMN2POLBCCR3 | |
| SCHEMBL4577310 | 0.88 | FAAH (0.68) | MEN1KMT2ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL4579206 | 0.85 | GRIN2D (0.68) | MEN1KMT2ASMN1; SMN2ALDH1A1GRIN1 | |
| SCHEMBL13234951 | 0.85 | SMN1; SMN2 (1.00) | MEN1KMT2ASMN1; SMN2CCR3 | |
| SCHEMBL4591719 | 0.83 | MEN1 (0.55) | MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4579179 | 0.83 | SMN1; SMN2 (0.79) | MEN1KMT2ASMN1; SMN2CCR3GRIN1 | |
| SCHEMBL7244230 | 0.81 | MEN1 (0.69) | MEN1KMT2ASMN1; SMN2ALDH1A1GRIN1 | |
| SCHEMBL5359069 | 0.79 | CCR3 (0.62) | MEN1KMT2ASMN1; SMN2POLBCCR3 | |
| SCHEMBL4958207 | 0.79 | MEN1 (0.65) | MEN1KMT2ASMN1; SMN2POLBCCR3 | |
| SCHEMBL4576852 | 0.78 | SMN1; SMN2 (0.72) | MEN1KMT2ASMN1; SMN2POLBCCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435744-B2 | Piperidine derivatives as NMDA receptor antagonists | GEDEON RICHTER VEGYESZETI GYAR RT (HU) | 2008-10-14 | — | — | US | disclosed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | disclosed |
| EP-1409477-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010159-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | GRIN1, GRIN2D, GRIN2C | MEN1 2584/4885KMT2A 1234/4885SMN1; SMN2 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.